Share on LinkedInShare on LinkedIn

ARTICLE · 16 JULY 2026

Antitrust & Competition Healthcare 1H 2026 Update

Federal and state antitrust regulators maintained aggressive enforcement in healthcare markets during the first half of 2026, with the FTC's new Healthcare Task Force coordinating scrutiny of mergers, PBM rebate practices, and restrictive payor contracts. Private equity healthcare investments face expanding state-level filing requirements, while algorithmic pricing in out-of-network reimbursement remains a target for both government enforcers and private litigation.

United StatesAntitrust/Competition Law

Healthcare remained a top priority for antitrust enforcers in the first half of 2026 as federal and state regulators remained active through a range of enforcement actions and policy initiatives.

Key Takeaways

  • FTC Healthcare Task Force. The FTC’s newly launched Healthcare Task Force signals sustained, coordinated scrutiny of both healthcare deals and commercial arrangements.
  • Structural remedies continue to be the preferred approach for mergers between direct competitors. Sevita/BrightSpring and Ascension/AmSurg confirm the FTC’s continued preference for facility divestitures over blocking transactions outright.
  • PBM business models are being reshaped. The FTC’s pharmacy benefit manager (PBM) settlements point to a potential shift away from rebate-driven models toward net-cost, fee-based pricing.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from